Efficacy and Safety of GS-6624 Combined with FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma
What is the purpose of this trial?
Primary Objective and Primary Endpoint - To compare the additive efficacy of GS-6624 vs. placebo in combination with FOLFIRI as measured by improvement in progression free survival (PFS).
- 18 Years and older
- Gilead Sciences
- Last Updated:
- Study HIC#: